Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Molnupiravir→

Molnupiravir Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
2492423-29-5
Molecular formula
C13H19N3O7
Molecular weight
329.31 g/mol
Drug class
Antiviralnucleoside analogue prodrug targeting SARS-CoV-2 RNA polymerase
Mechanism of action
A prodrug converted intracellularly to N-hydroxycytidine triphosphate, which is incorporated by viral RNA-dependent RNA polymerase and causes accumulation of errors in the viral genome (viral error induction or lethal mutagenesis).
Indications / reported uses
  • Treatment of mild-to-moderate COVID-19 in adults at increased risk of progression when alternative authorised treatment options are not appropriate, subject to current local authorisation and product-label criteria.

Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1b0da643-ab23-4a0b-a9ec-a434522446d0 · https://pmc.ncbi.nlm.nih.gov/articles/PMC10851176/

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Molnupiravir Environmental Risk Assessment (ERA) (the Molnupiravir ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.